Treatment for Methamphetamine Abuse and Dependence Richard A. Rawson, Ph.D. Alice Huber, Ph.D. Paul Brethen, M.A. Walter Ling, M.D. Matrix/UCLA/LAARC Supported.

Slides:



Advertisements
Similar presentations
The Voice of Recovery: Effectively Treating Methamphetamine Users and their Families Michael S. Shafer, Ph.D.
Advertisements

Telephone Continuing Care James R. McKay, Ph.D. Center on the Continuum of Care in the Addictions Department of Psychiatry University of Pennsylvania Philadelphia.
High Intensity Trainee (HIT) Role. What will you be doing? Clinical practice 3 days per week 2 days at University Based in a variety of locations i.e.
1 Intervening in the Recovery Process Michael L. Dennis, Ph.D. Christy K Scott, Ph.D. Chestnut Health Systems, Bloomington &Chicago, IL U.S.A. Presentation.
Medication Assisted Treatment: An Introduction Deborah A. Orr, Ph.D., RN Remington College School of Nursing.
Swinomish Wellness Program
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Mood Disorders. Level of analysis Depression as a symptom Depression as a syndrome Depression as a disorder.
Developed for the Alcohol Medical Scholars Program 1 Alcohol and Cocaine Katie McQueen, M.D. Baylor College of Medicine.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D Adjunct Associate Professor Semel Institute for Neuroscience and Human.
Alcohol Medical Scholars ALCOHOLISM AND POSTTRAUMATIC STRESS DISORDER Joe E. Thornton, M.D.
MENTAL HEALTH Understanding Mental Illness. Defining Mental Illness Clinical definition Clinically significant behavioral problems Clinically significant.
Psychosis: Early Identification and Intervention Easter Seals Michigan.
Rural Crime & Justice Center A University Center of Excellence Minot, North Dakota.
Methamphetamine A Post-War Epidemic FACTORS Large quantities Disorganization “Work pills” 500,000 addicts Reduced supply Increased heroin JAPAN.
The European Network for Traumatic Stress Training & Practice
1 Integrative Treatment of Complex Trauma (ITCT) and Self Trauma Model for Traumatized Adolescents Cheryl Lanktree, Ph.D. and John Briere, Ph.D. MCAVIC-USC.
Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,
UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.
Psychotic disorders.
Overview of Mental Health and Addiction Disorders Thanks to John Mogk, M.A. Clinical Coordinator Maple Ridge Treatment Centre for original version of this.
Methamphetamine Effects and Treatment Options Richard Rawson, Ph.D. UCLA ISAP La Jolla, Ca. Oct 2004.
Treatment 101 Substance Abuse Basics West Coast Consulting Wanda King
Comorbidity: Best Practice Behavioral Health Approaches for American Indians and Alaska Natives San Diego, California June 28-30, 2005 Dale Walker, MD,
Methamphetamine: Brain and Behavior: Research Findings Richard. A. Rawson, Ph.D. UCLA Integrated Substance Abuse Programs Los Angeles California
Methamphetamine and the Brain: New Knowledge; New Treatments Methamphetamine and the Brain: New Knowledge; New Treatments Richard A. Rawson, Ph.D Adjunct.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.
Depression Rebecca Sposato MS, RN. Depression  An episode lasting over two weeks marked by depressed mood or inability to feel enjoyment  Very common.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
Recognizing Mental Health Issues in the Workplace Dr. Kent Youngman & Dr. Greta Mayer Mental Health & Recovery Board of Clark, Greene and Madison Counties.
Outcomes of Treatment for Methamphetamine Use: LA County (“Treatment-as-Usual”) M.-L. Brecht UCLA Integrated Substance Abuse Programs CATES 3/30/2004.
Arthur’s Quick & Dirty Pre-read. Table 75.6 Basic management essentials Keep patient alive (maintain airway and circulation) Get history from witnesses.
Treatments for Methamphetamine- Related Disorders Richard A. Rawson, Ph.D, Professor Integrated Substance Abuse Programs Semel Institute for Neuroscience.
Treatments for Methamphetamine-Related Disorders Richard A. Rawson, Ph.D. UCLA Integrated Substance Abuse Program, Sacramento, CA Dec 2, 2004
The Effectiveness of Psychodynamic Therapy and Cognitive Behavior Therapy in the Treatment of Personality Disorders: A Meta-Analysis. By Falk Leichsenring,
Recognizing depression : specific issues among the female gender
Psychostimulants Lesson 19. Psychostimulants n Cocaine l alkaloid from coca plant n Amphetamines (synthetics) l similar fx & mechanisms l all related.
EMPIRICALLY-SUPPORTED TREATMENTS FOR STIMULANT DEPENDENCE RICHARD A. RAWSON, Ph.D. UCLA INTEGRATED SUBSTANCE ABUSE PROGRAMS (ISAP) October 9, 2004.
Remediation Power Point
Engagement, Adherence, Transition to Community & Course Wrap-Up Demian Rose, MD Rachel Loewy, PhD Linda May, PhD, MFT.
Bipolar Disorder and Substance Use Disorders Bipolar I Disorder Includes one or more Manic Episodes or Mixed Episodes, sometimes with Major Depressive.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
Depressive And Bipolar Disorders Psychology. Mood disorders  Characterized by significant and chronic disruption in mood is the predominant symptom,
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
7.3 Drugs and Consciousness Psychoactive Drugs: chemicals that affect the nervous system and result in altered consciousness.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
Mental Health Emergencies. Mental Health Mental Health in the ED Mental Health in the ED Focused surveyFocused survey History of present illness & patient’s.
Treatments for Methamphetamine- Related Disorders Richard. A. Rawson, Ph.D. UCLA Integrated Substance Abuse Programs Los Angeles California
Treatments for Methamphetamine-Related Disorders I (General)
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
بسم الله الرحمن الرحيم Dr: Samah Gaafar Hassan Al-shaygi.
Cognitive Behavioral Therapy as Treatment for Cocaine Abuse and Dependency Bre Sullivan Dayton Latty.
Treatments for Methamphetamine-Related Disorders Richard A. Rawson, Ph.D. UCLA Integrated Substance Abuse Program, Vancouver, Canada Nov, 16,
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
Psychiatric Consequences of Methamphetamine Abuse Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
IN THE NAME OF GOD Seyed Alireza Haji seyed javadi MD Psychiatrist Assistant Professor and Head Department of Psychiatry school of Medicine Qazvin University.
Management of Geriatric Psychiatric Disorders Arash Mirabzadeh Psychiatrist University of Social Welfare and Rehabilitation Sciences.
Gregory S. Brigham, Ph.D., CEO
Bipolar Disorder and Substance Use Disorders
Presented by J. Arzaga, MSN, RN
Diabetes and Psychiatric Disorders: Can they Co-exist?
Efforts to Reduce Meth Use and Sexual Risk
Psychological Support for Kleine-Levin Syndrome
Bell Work What must be present for behavior to be considered “abnormal”?
Presentation transcript:

Treatment for Methamphetamine Abuse and Dependence Richard A. Rawson, Ph.D. Alice Huber, Ph.D. Paul Brethen, M.A. Walter Ling, M.D. Matrix/UCLA/LAARC Supported by NIDA and CSAT

MA Treatment Issues Acute MA Overdose Acute MA Overdose Acute MA Psychosis Acute MA Psychosis MA “Withdrawal” MA “Withdrawal” Initiating MA Abstinence Initiating MA Abstinence MA Relapse Prevention MA Relapse Prevention Protracted Cognitive Impairment and Symptoms of Paranoia Protracted Cognitive Impairment and Symptoms of Paranoia

Acute MA Overdose Slowing of Cardiac ConductionSlowing of Cardiac Conduction Ventricular IrritabilityVentricular Irritability Hypertensive EpisodeHypertensive Episode Hyperpyrexic EpisodeHyperpyrexic Episode CNS Seizures and AnoxiaCNS Seizures and Anoxia

Acute MA Psychosis Extreme Paranoid IdeationExtreme Paranoid Ideation Well Formed DelusionsWell Formed Delusions Hypersensitivity to Environmental StimuliHypersensitivity to Environmental Stimuli Stereotyped Behavior “Tweaking”Stereotyped Behavior “Tweaking” Panic, Extreme FearfulnessPanic, Extreme Fearfulness High Potential for ViolenceHigh Potential for Violence

Treatment of MA Psychosis Typical ER Protocol for MA PsychosisTypical ER Protocol for MA Psychosis –Haloperidol - 5mg –Clonazepam - 1 mg –Cogentin - 1 mg –Quiet, Dimly Lit Room –Restraints?

Treatment of MA Disorders Traditional TreatmentsTraditional Treatments –Therapeutic Community –Minnesota Model –Outpatient Counseling –Psychotherapy

MA “Withdrawal” - Depression- Paranoia - Fatigue- Cognitive Impairment - Anxiety- Agitation - Anergia- Confusion Duration: 2 Days - 2 WeeksDuration: 2 Days - 2 Weeks

Treatment of MA “Withdrawal” Hospitalization/Residential Supervision if:Hospitalization/Residential Supervision if: –Danger to Self or Others, or, so Cognitively Impaired as to be Incapable of Safely Traveling to and from Clinic. –Otherwise Intensive Outpatient Treatment

Treatment of MA “Withdrawal” Intensive Outpatient TreatmentIntensive Outpatient Treatment –No Pharmacotherapy Available –Positive, Reassuring Context –Directive, Behavioral Intervention –Educate Regarding Time Course of Symptom Remission –Recommend Sleep and Nutrition –Low Stimulation –Acknowledge Paranoia, Depression

Treatment of MA Disorders State of Empirical EvidenceState of Empirical Evidence –No Information on TC or “Minnesota Model” Approaches –No Pharmacotherapy with Demonstrated Efficacy –Results of Cocaine Treatment Research Extrapolated to MA Treatment

Initiating MA Abstinence Key Clinical IssuesKey Clinical Issues –Depression –Cognitive Impairment –Continuing Paranoia –Anhedonia –Behavioral/Functional Impairment –Hypersexuality –Conditioned Cues –Irritability/Violence

Initiating MA Abstinence Key Elements of TreatmentKey Elements of Treatment –Structure –Information in Understandable Form –Family Support –Positive Reinforcement –12-Step Participation No Pharmacologic Agent Currently AvailableNo Pharmacologic Agent Currently Available

Follow-up of 114 MA Users Treated with Matrix Model

Mean Duration of Follow-up - 40 Months

Follow-up of 114 MA Users Treated with Matrix Model

MA - Cocaine Follow-up Comparison Matrix Clinic in Rancho Cucamonga, San Bernardino County located 50 miles East of Los AngelesMatrix Clinic in Rancho Cucamonga, San Bernardino County located 50 miles East of Los Angeles One to five years follow-up of 100 MA and 100 cocaine users in a CSAT funded studyOne to five years follow-up of 100 MA and 100 cocaine users in a CSAT funded study

MA - Cocaine Follow-up Comparison